Patents Assigned to Neomed Institute
-
Patent number: 10836742Abstract: This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.Type: GrantFiled: August 11, 2016Date of Patent: November 17, 2020Assignee: Neomed InstituteInventors: Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
-
Patent number: 10703740Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.Type: GrantFiled: August 12, 2016Date of Patent: July 7, 2020Assignee: Neomed InstituteInventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
-
Patent number: 10519151Abstract: This application relates to substituted [1,2,4]triazolo[4,3-a]pyridines of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted [1,2,4]triazolo[4,3-a]pyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.Type: GrantFiled: January 27, 2017Date of Patent: December 31, 2019Assignee: Neomed InstituteInventors: Malken Bayrakdarian, Stephen Claridge, Andrew Griffin
-
Patent number: 10501459Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.Type: GrantFiled: October 20, 2016Date of Patent: December 10, 2019Assignee: Neomed InstituteInventors: Mehrnaz Pourashraf, Marc-Andre Beaulieu, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
-
Patent number: 10501438Abstract: This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.Type: GrantFiled: August 11, 2016Date of Patent: December 10, 2019Assignee: Neomed InstituteInventors: Guillaume Jacquemot, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
-
Patent number: 10111883Abstract: Provided herein are methods for the treatment of avoiding loss of taste response while treating a chronic cough patient with a selective P2X3 modulator.Type: GrantFiled: March 26, 2018Date of Patent: October 30, 2018Assignees: BELLUS HEALTH COUGH INC., NEOMED INSTITUTEInventors: Denis Garceau, Antonios Matzouranis, Roberto Bellini, Kemal Payza, Nathalie Chauret, Susan E. Browne
-
Patent number: 9814725Abstract: This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processesor making such a compound, and intermediates used in such processes.Type: GrantFiled: February 2, 2017Date of Patent: November 14, 2017Assignee: NEOMED INSTITUTEInventors: Christophe Buon, Louis-David Cantin, Yun-Jin Hu, Xuehong Luo, Miroslaw Jerzy Tomaszewski
-
Patent number: 9598409Abstract: This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.Type: GrantFiled: January 31, 2014Date of Patent: March 21, 2017Assignee: Neomed InstituteInventors: Christophe Buon, Louis-David Cantin, Yun-Jin Hu, Xuehong Luo, Miroslaw Jerzy Tomaszewski
-
Patent number: 8633235Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.Type: GrantFiled: September 24, 2004Date of Patent: January 21, 2014Assignee: Neomed InstituteInventors: Ziping Liu, Daniel Pagé, Christopher Walpole, Hua Yang
-
Patent number: 8530467Abstract: This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.Type: GrantFiled: May 16, 2012Date of Patent: September 10, 2013Assignee: Neomed InstituteInventors: Louis-David Cantin, Xuehong Luo, Miroslaw Jerzy Tomaszewski